ArticleClinical journal of the American Society of Nephrology : CJASN2025
Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report.BMC nephrology · 2026Article
- Systemic inflammatory profiles are associated with long-term kidney failure and patient mortality in chronic kidney disease.Clinical kidney journal · 2026Article
- Earlier Hematuria Negative Conversion Was an Independent Predictor for Nephrotic Remission in Patients with Primary Membranous Nephropathy and Nephrotic Syndrome.American journal of nephrology · 2026Article
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- Short-term clinical remission rates and adverse reactions of rituximab compared to cyclosporine in patients with refractory membranous nephropathy (MN).American journal of translational research · 2026Article
- Progress Toward a Better Predictor of Remission in Anti-Phospholipase A2 Receptor-Associated Membranous Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management.Frontiers in immunology · 2025Review
- Hepatic tuberculosis induced by rituximab treatment for C1q nephropathy with minimal change disease: a case report.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.